HormonePitocinSyntocinon

Oxytocin

Cyclic nonapeptide · FDA-approved uterotonic · contested "love hormone"

Oxytocin is a small hormone (a nonapeptide — a chain of nine amino-acid building blocks) made in the hypothalamus and released by the posterior pituitary. Its two best-understood, body-based jobs are making the uterus contract and triggering milk letdown during breastfeeding. Because it is a uterotonic (a drug that makes the uterus contract), a synthetic version sold as Pitocin/Syntocinon is given by IV drip or injection in hospitals to start or strengthen labor and control bleeding after birth — for these obstetric uses the evidence is strong and the drug is FDA-approved. Separately, oxytocin became famous as the "love hormone," given as a nasal spray in research to test effects on trust, empathy, social anxiety, and bonding. This is where the science gets shaky: many of the earliest, most-cited single-dose findings — including the famous 2005 "oxytocin increases trust" study — have failed to replicate in larger, better-powered experiments, and critics argue very little of an intranasal dose actually reaches the brain. The honest bottom line is to trust the obstetric use and be skeptical of the social/bonding/libido marketing. Oxytocin is not an approved treatment for anxiety, autism, libido, or "connection," and vendors selling it for those purposes are extrapolating well beyond the replicated evidence.

The short version

Oxytocin is a small hormone (a "nonapeptide" — a chain of nine amino-acid building blocks) made in the hypothalamus and released by the posterior pituitary gland. Its two best-understood, body-based jobs are making the uterus contract and triggering milk letdown (the milk-ejection reflex) during breastfeeding. Because it is a uterotonic (a drug that makes the uterus contract), a synthetic version sold as Pitocin/Syntocinon is given by IV drip or injection in hospitals to start or strengthen labor and to control bleeding after birth. For these obstetric uses the evidence is strong and the drug is FDA-approved.

Separately, oxytocin became famous as the "love hormone" or "bonding hormone." A large research literature gave it as a nasal spray to healthy volunteers to test effects on trust, empathy, social anxiety, and pair-bonding. This is where the science gets shaky. Many of the earliest, most-cited single-dose findings — including the famous 2005 "oxytocin increases trust" study — have failed to replicate in larger, better-powered experiments. Critics have also argued that very little of an intranasal dose actually reaches the brain, so some reported "central" effects may be questionable.

The bottom line: trust the obstetric use; be skeptical of the social, bonding, and libido marketing. Oxytocin is not an approved treatment for anxiety, autism, libido, or "connection," and compounders or peptide vendors selling it for those purposes are extrapolating well beyond the replicated evidence.

Molecular identity

Specs

Molecular weight: 1007.2 g/mol
Molecular formula: C43H66N12O12S2
Monoisotopic mass: 1006.4365 Da
CAS / UNII: 50-56-6 · 1JQS135EYN
Water solubility: Soluble in water (and butanol)
Half-life: ~1–6 min (plasma)

Sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (9 AA)PubChem CID 439302
Structure / class: Cyclic nonapeptide; intramolecular Cys1–Cys6 disulfide bond + C-terminal amidePubChem CID 439302
Molecular target: Oxytocin receptor (OXTR) agonist — Gq/calcium signalingPMID 11274341
Brand / approval: Pitocin / Syntocinon — FDA-approved uterotonic (IV/IM) for labor induction/augmentation & postpartum hemorrhage; NOT approved for social/bonding/anxiety usePitocin FDA label
Anti-doping status: Not named on the WADA 2026 Prohibited List (permitted by inference)WADA 2026

Plain English

Mechanism

Oxytocin acts on the oxytocin receptor (OXTR), a G-protein-coupled receptor (a cell-surface switch) that signals mainly through a rise in intracellular calcium. In the uterus's smooth muscle that calcium rise activates the contractile machinery, producing contractions; receptor density climbs near term, which is why oxytocin is far more effective for labor at term than preterm. In the breast it contracts the cells around the milk glands to produce the milk-ejection reflex. These peripheral, body-side effects are well established in humans.

The central, brain-side story is where the honesty caveat lives. In animal models — strongly in rodents and prairie voles — oxytocin in the brain shapes pair-bonding, maternal behavior, and social recognition through OXTR in regions like the amygdala and nucleus accumbens. Whether intranasal oxytocin reproduces these effects in humans is the crux of the controversy. Two methodological critiques anchor the skepticism: Leng and Ludwig argue that after a nasal dose only trace amounts plausibly reach the cerebrospinal fluid while blood levels are driven supraphysiologic, and Walum and colleagues showed the intranasal literature is severely underpowered (average statistical power roughly 12–16%), so many published positive effects may be false positives.

Keep the two apart: the bonding and social mechanism is robust in animals; its translation to humans via nasal spray is where the evidence breaks down. Oxytocin also differs from the antidiuretic hormone vasopressin by only two amino acids, which gives it mild water-retaining activity at high doses — a real clinical consideration, not a social one.

Sources:PMID 11274341 PMID 26049207 PMID 26210057

Why people reach for it

Potential benefits

Oxytocin draws two very different crowds — and the honest split matters. Here's what people reach for it for, with the strong obstetric use and the contested social use kept apart.

A pro-social, bonding-context reach (contested in humans) — Its famous appeal: people use intranasal oxytocin around social, intimate, or therapy settings hoping to feel more connected and trusting. The honest catch — that effect is robust in animals but has largely failed to replicate in well-powered human studies, so it's a why-people-use-it, not a proven benefit.
Taken around closeness and intimacy — Because the hormone's biology is tied to touch, warmth, and pair-bonding, people reach for it before an intimate or partner context — sometimes alongside PT-141, which adds an arousal mechanism oxytocin doesn't cover.
A calm, anxiolytic-leaning social aid (research-reported, not proven) — Some use it hoping to take the edge off social anxiety; acute single doses are generally mild and well-tolerated, but the bigger issue for this use is unproven efficacy, not acute harm.
The genuinely strong use is obstetric (and hospital-only) — Where oxytocin's evidence is rock-solid is as the FDA-approved drug Pitocin — an IV/IM uterotonic for inducing labor and preventing postpartum hemorrhage. That's a monitored hospital use, not a community one, and it's the half of oxytocin's story that's actually settled science.

Sources:PMID 31032882 PMID 10949753 PMID 15931222 PMID 32514040 PMID 11274341

What people reach for oxytocin for — the obstetric use is strong, replicated, and FDA-approved; the social/bonding/intimacy use is contested and largely failed to replicate in humans. This is not a claim that it treats anxiety, autism, low libido, or improves "connection."

Implied timing

Best time to dose

Implied best time

Situational (as needed)

Oxytocin is dosed around the moment it's wanted — typically ~30–45 minutes before a social, intimate, or therapy setting — not on a daily clock.

It's short-acting (plasma half-life ~1–6 minutes), so the effect is brief and acute — which is exactly why it's timed just ahead of the desired window rather than taken at a fixed daily hour.
The behavioural research that defined its use dosed intranasal oxytocin ~30–45 minutes before a social task, so that pre-context window is the convention people follow.
It's used situationally, not chronically: chronic daily dosing has generally produced null results, there's no established maintenance schedule, and acute single-occasion use is both the studied pattern and the more defensible one given the contested evidence.
Most community users cap it at a few times per week tied to specific occasions — and many avoid late-evening dosing if the goal is calm social interaction, since some report mild stimulating effects in quiet settings.

No study sets an ideal time of day for oxytocin, because it isn't a daily-clock compound — this is reasoned from its short half-life and how it's used. Where most peptides cluster in a midday-to-evening window, oxytocin is a situational exception: dosed before the social or intimate occasion it's aimed at.

Sources:DailyMed (Pitocin)

How to run it

Dosing & protocol

Oxytocin is intranasal-primary for community behavioural use — that is the route of the social/bonding research literature and the most common way people self-administer it outside a hospital. It is also used subcutaneously in the research-peptide context, and the calculator is built for that route. Both are covered below. Honest framing first: the obstetric IV evidence (Pitocin) is strong; the intranasal social/bonding use is contested and the effects it was designed to produce have largely failed to replicate. Every number below is drawn from the research literature and community convention — not an approved consumer regimen.

Honest caveat up front: oxytocin has STRONG evidence as an IV hospital drug (Pitocin — FDA-approved for labor and postpartum hemorrhage) and CONTESTED evidence as an intranasal social/bonding peptide. A large registered replication (Declerck 2020, >95% power) found no effect on trust, and critics dispute whether meaningful amounts of an intranasal dose reach the brain. Community intranasal use is convention layered on shaky science — not an approved consumer regimen.

Tiered dose ranges

Community intranasal doses for behavioural goals are measured in International Units (IU); subcutaneous doses are the same molecule measured in mcg. Note: 1 IU of oxytocin ≈ 1.68 mcg (WHO reference standard).

Low / entry (intranasal):: 10 IU per session — used as a first-use tolerance check or a gentle social-context dose; split as 5 IU per nostril.
Standard (intranasal):: 24 IU per session — the most-cited research convention; 12 IU per nostril, administered roughly 30–45 minutes before an intended social interaction, physical contact, or therapeutic context. This is how the majority of intranasal studies were designed.
Upper community range (intranasal):: 40 IU per session — the higher end of what circulates in community use; some users report diminishing returns above 24 IU. Not supported by dose-ranging trial evidence.
Subcutaneous (research-peptide route):: ~40 mcg once (≈ 24 IU) — matching the intranasal research dose by mass; injected subcutaneously. Subcutaneous bioavailability is higher than intranasal, so the brain-delivery debate does not apply here — but the behavioural effect on trust/bonding in humans also lacks robust replication regardless of route.
Obstetric IV (hospital only — not a community route):: 0.5–2 milliunits/min IV titrated infusion for labor induction/augmentation; IM injection for postpartum hemorrhage prophylaxis. This is clinician-administered with a controlled infusion device. Its very short plasma half-life (~1–6 min) is exactly why labor dosing is a continuous drip, not a single injection — note this for context, not community replication.

Administration — intranasal + subcutaneous

Intranasal is the community primary route for behavioural effects; subcutaneous is the research-peptide alternative the calculator serves. IV is hospital-only obstetric context — not covered here as a practical instruction.

Intranasal — how to dose:: Reconstituted oxytocin is administered as a nasal spray via an atomizer, or as drops with a dropper. Divide the dose evenly across both nostrils (e.g. for 24 IU, 12 IU per side). Sniff gently after instilling — enough to move the solution toward the olfactory epithelium, not hard enough to clear it down the throat. Avoid blowing the nose for 10 minutes before or after dosing.
Why intranasal — nose-to-brain rationale:: The proposed mechanism for intranasal administration is the olfactory and trigeminal nerve pathway, which offers a partial route to the brain bypassing the blood-brain barrier. That is the theoretical rationale. The honesty caveat: Leng & Ludwig (2016) argue only trace amounts plausibly reach the cerebrospinal fluid via this path, while blood oxytocin is driven to supraphysiologic levels. Brain delivery is disputed, not established — but intranasal remains the community and research convention for behavioural use.
Subcutaneous — site and rotation:: Injected into subcutaneous fat at the abdomen (a couple of inches clear of the navel), the outer thigh, or the love-handle area. Rotate sites between doses to avoid irritation or lipohypertrophy.
Subcutaneous — measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. At a standard 2 mg vial + 2 mL bacteriostatic water mix (1,000 mcg/mL): 40 mcg = 4 IU on the syringe. The on-page calculator adjusts for any vial size.
Timing:: For behavioural use: intranasal is typically timed 30–45 minutes before a social interaction, physical contact, or therapeutic context — that is the window most research studies used before a task. Subcutaneous is similarly timed ~30 min ahead. Avoid late-evening dosing if the goal is calm social interaction; some users report mild stimulating/anxious-adjacent effects in quiet settings.
Food window:: No documented food interaction for either route. Both can be administered independent of meals.

Cycle / use pattern

Oxytocin is most often used acutely and situationally — not chronically. That is both the community convention and, frankly, the most defensible pattern given contested behavioural evidence.

Acute / situational use:: A single dose on a given day before a social context, therapy session, or intended bonding experience — then not again until the next occasion. No continuous cycle. This is the pattern most studies used and the most common community approach.
Why chronic use is not standard:: Chronic intranasal oxytocin trials in clinical populations (including autism studies) have generally produced null primary-outcome results. There is no established maintenance cycle, no proven benefit from repeated daily dosing, and receptor desensitisation with prolonged use is a theoretical concern given the peptide's mechanism. Acute situational use avoids this question.
Frequency cap:: Most community users limit to 2–3 times per week at most, aligned with specific social contexts rather than a fixed daily schedule. Daily use is not supported.

Reconstitution at a glance

Mixing math only — the on-page calculator does this live. Quick reference for a 2 mg vial (the most common vial size):

Mixing:: 2 mg vial + 2 mL bacteriostatic water = 1,000 mcg per mL. On a 100-unit (1 mL) insulin syringe: 40 mcg = 4 IU · 20 mcg = 2 IU. For intranasal use, the same reconstituted solution is loaded into a nasal atomizer or dropper — no separate dilution needed for standard doses.
IU to mcg conversion:: 1 IU of oxytocin ≈ 1.68 mcg (WHO International Standard). At this mix: 24 IU ≈ 40 mcg ≈ 4 syringe units (IU). The calculator converts automatically.

Sources:PMID 10949753 PMID 15931222 PMID 32514040 PMID 26049207 PMID 26210057 DailyMed (Pitocin)

Substrate the signal needs

Nutritional cofactor precision

Oxytocin cofactors map to three mechanisms: AMPLIFY — the behaviours that evolved with the hormone and that actually drive endogenous oxytocin release; SUPPLY — the biochemical substrate oxytocin's synthesis and amidation depends on; SUPPORT — the receptor calcium-signalling the hormone works through. None of this is an oxytocin nutrition study; it is the biochemistry and behavioural science of the hormone applied as reasoned cofactors.

Reasoned from oxytocin's amidation biochemistry + receptor calcium-signalling + behavioural science — not an oxytocin cofactor trial. The honesty caveat carries forward: the social/bonding effects these "amplify" are the contested intranasal claims, so do not read any of this as a proven pathway to "connection."

Amplify — social-behaviour inputs (the on-mechanism cofactor)

The headline cofactor for oxytocin is not a supplement — it is the set of social behaviours the hormone evolved around. These are the inputs that most reliably raise endogenous oxytocin in studies of healthy humans.

Physical touch and warmth:: Warm social touch — a hug, a hand on the shoulder, sustained physical closeness — is the best-evidenced trigger of endogenous oxytocin release. If the goal is more oxytocin activity, this lever is far more reliable than a spray of contested brain-delivery. Warm ambient temperature has also been associated with oxytocin tone in some work.
Eye contact and social connection:: Mutual gaze and active face-to-face social engagement are associated with oxytocin release in both humans and, strongly, in dogs and their owners. Intentional social presence — conversation, eye contact, connection — is an on-mechanism input.
Singing, rhythm, and group movement:: Synchronised group activities — communal singing, choral or rhythmic movement — have been associated with oxytocin-mediated social bonding in several studies. Worth noting because it is a specific and often overlooked behavioural lever.
Frame on all of the above:: These are not substitutes for the peptide — they are what the peptide's mechanism evolved to work alongside. Using intranasal oxytocin in an isolating, screen-facing, low-contact context removes the social inputs the hormone is designed to act on.

Supply — amidation and synthesis substrate (vitamin C · copper · magnesium)

Oxytocin is biologically active only because its C-terminal glycine is converted to an amide group — a chemical finishing step that completes the hormone. The enzyme that does this (PAM — peptidylglycine alpha-amidating monooxygenase) requires vitamin C and copper as its direct cofactors. This is textbook enzymology, not supplementation lore.

Vitamin C — 500–1,000 mg/day:: Ascorbate (vitamin C) is a required electron donor for PAM. Without adequate vitamin C, PAM activity drops and C-terminal amidation of oxytocin (and other neuropeptides) is impaired. This is basic enzymatic biochemistry. Timing: with food, daily.
Copper — 2 mg/day:: Copper is the metallic cofactor of PAM's copper-binding catalytic domain — no copper, no amidation. Most people consuming adequate zinc without balancing copper run a relative copper deficit over time. 2 mg copper bisglycinate or glycinate daily covers this without excess. Note: high-dose zinc (>30 mg/day) competes with copper absorption — balance the ratio.
Magnesium — 200–400 mg/day (glycinate form, evening):: The oxytocin receptor (OXTR) signals through intracellular calcium. Magnesium regulates calcium-channel dynamics and NMDA-receptor tone, and adequate magnesium is associated with a calmer, less hyperactivated baseline — a plausible support for OXTR calcium-signalling and for the social calm oxytocin is thought to promote. Glycinate form in the evening for sleep benefit.

Mitigate — minimal; one note on vasopressin cross-activity

Oxytocin's acute intranasal side-effect profile is mild. The one structural consideration worth flagging: oxytocin and vasopressin differ by only two amino acids, so high intranasal doses may carry mild water-retaining activity.

Hydration awareness at higher doses:: At doses toward the upper community range (40 IU), mild vasopressin-like antidiuretic activity is a theoretical cross-activity given the structural homology. This is a well-characterized risk only in the high-dose IV obstetric setting (hyponatremia with large fluid volumes), not a documented concern at intranasal research doses — but worth noting for users who routinely dose high and consume large fluid volumes.

Combinations + timing

Stacking notes + timing windows

Honest upfront: oxytocin's "stack" is mostly behavioural and contextual rather than peptide-peptide. The social/bonding effect the community layers on top of other compounds is itself the contested intranasal claim. Any peptide pairing is therefore doubly unproven — and where a pairing is named, it is reasoned from mechanism, not studied head-to-head.

These are user combinations reasoned from complementary mechanisms — not regimens studied together, and oxytocin's own intranasal social/bonding effect remains contested. Each pairing is doubly unproven. Community convention, not evidence-based protocol.

Oxytocin + Selank

The most reasoned intranasal pairing: oxytocin for pro-social tone, Selank for anxiolytic calm — two different levers on the same social-comfort goal.

Why it works:: Selank is a tuftsin analog with a GABAergic/serotonergic anxiolytic mechanism — it reduces social anxiety without sedation. Oxytocin is thought to bias social perception toward trust and affiliation (the contested behavioural claim). The logic: if oxytocin pushes social engagement and Selank removes the anxiety brake on that engagement, the pairing addresses the same goal from complementary angles. Different levers, not the same one twice.
The protocol (intranasal):: Oxytocin 24 IU intranasally + Selank 300 mcg intranasally, both administered 30–45 minutes before a social context, therapy session, or intended interaction. Both as nasal spray or drops; same timing window is the community convention.
The protocol (subcutaneous alternative):: Oxytocin ~40 mcg SC + Selank 300 mcg SC, both in the 30–45 min pre-session window.
Outcome:: Reached for in social-anxiety, therapy-augmentation, and couples-context use. Honest caveat: oxytocin's own behavioural effect in humans is the contested layer here — the Selank anxiolytic effect is the better-supported half of the pair.

Oxytocin + PT-141

A pairing aimed at the intimacy-and-connection context — oxytocin for the affiliative/bonding signal, PT-141 for arousal via the melanocortin system.

Why it works:: PT-141 (bremelanotide) acts on MC3R/MC4R receptors in the hypothalamus, a well-characterized mechanism for sexual arousal that is independent of oxytocin's affiliative/trust pathway. Different receptor systems, different functional contributions — arousal and bonding are complementary rather than redundant.
The protocol:: Oxytocin 24 IU intranasally (or ~40 mcg SC) + PT-141 1–2 mg SC, both administered ~45–60 minutes before an intimate context. PT-141 is the slower-onset compound (onset 1–2 hours) — dose it slightly ahead of the oxytocin if timing precisely.
Outcome:: Reached for in intimate-context and sexual-health use. Both compounds are doubly hedged: oxytocin's bonding claim is contested; PT-141 has the stronger mechanistic and (in bremelanotide) FDA-approval evidence for arousal, but the combination itself is user convention, not a studied pairing.

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.04 mL
Doses per vial: 50
Concentration: 1 mg/mL

One vial lasts

Daily: 50 days
Every other day: 100 days
5×/week: 70 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

In the obstetric IV setting — where the medically important risks live — the principal dose-limiting hazard is uterine hyperstimulation or tetanic contractions, which can progress to uterine rupture and fetal distress. At high IV doses given with large fluid volumes, oxytocin's vasopressin-like antidiuretic activity can cause hyponatremia (water intoxication), which in severe cases leads to seizures, coma, or death. Cardiovascular effects include transient hypotension with rapid IV, severe hypertension if combined with vasoconstrictors, and reported arrhythmias with inappropriate dosing; nausea and vomiting also occur, and anaphylactoid reactions are rare.

In the intranasal research setting the picture is very different: single 24 IU doses are generally mild and transient, with occasional headache, nasal irritation, or mild GI symptoms, and serious adverse events uncommon. The honest framing is that for intranasal use the bigger concern is lack of proven efficacy, not acute harm — whereas the high-dose IV obstetric use carries genuine, well-characterized risks that are exactly why it is a monitored hospital drug.

Sources:PMID 10949753 PMID 26210057

As reported in literature

Research dosing ranges

These are the doses and studies in the published literature, shown so the strong obstetric evidence is never confused with the contested social-cognition claims. Read the table as a whole: the obstetric rows are strong and replicated; the intranasal social-cognition rows are early positives that the high-powered replication and meta-analytic rows substantially undercut.

Dose	Route	Model	Outcome	Sources:
Prophylactic oxytocin post-delivery	IV / IM	Human — 23 trials, ~10,018 women (Cochrane)	Reduces postpartum hemorrhage (blood loss ≥500 mL) vs no uterotonics/placebo; established standard of care — strong, replicated	PMID 31032882
Titrated infusion (milliunits/min)	IV	Human — review of labor-induction practice	Effective induction/augmentation of labor at term; near-immediate uterine response, subsides ~1 h after stopping — strong	PMID 10949753
24 IU single dose	Intranasal	Human — 178 men (trust/investment game)	Original report: oxytocin increased trust — influential but NOT robustly replicated (see below)	PMID 15931222
24 IU single dose	Intranasal	Human — large registered replication (>95% power)	No effect of oxytocin on trusting behavior — direct failure to replicate the 2005 trust finding	PMID 32514040
Methodological analysis (not a dose)	—	Human — meta-analytic review of intranasal OT studies	Intranasal studies average ~12–16% statistical power; most published positive findings likely unreliable	PMID 26210057

Quick answers

Frequently asked

Is the "love hormone" / bonding effect real?

In animals, oxytocin in the brain clearly shapes bonding. In humans via nasal spray the evidence is weak, and many headline findings have failed to replicate — so the popular "love hormone" framing is overstated. It is not an approved treatment for connection, libido, or social anxiety.

Does intranasal oxytocin actually reach the brain?

It is disputed. Critics argue only trace amounts cross into cerebrospinal fluid while blood levels spike to supraphysiologic concentrations, casting doubt on the claimed central effects. This uncertainty is a core reason the social-cognition claims are questioned.

Didn't a famous study show oxytocin increases trust?

Yes — the 2005 Kosfeld study. But a large, high-powered registered replication in 2020 (over 95% statistical power) found no effect on trusting behavior, and a critical review concluded the trust evidence is not robust. The original finding did not hold up.

Is oxytocin FDA-approved for anything?

Yes — as Pitocin, for inducing or augmenting labor and managing postpartum hemorrhage. It is not approved for anxiety, autism, libido, or bonding.

Why is Pitocin given as a continuous drip?

Because oxytocin's plasma half-life is only about 1–6 minutes, so a single dose wears off almost immediately. A titrated IV infusion maintains a steady contraction pattern, and the uterine response subsides within about an hour of stopping it.

Is intranasal oxytocin dangerous?

Acute single doses are generally mild and well-tolerated — the real issue is unproven benefit, not acute toxicity. High-dose IV oxytocin in obstetrics, by contrast, carries serious hyperstimulation and hyponatremia risks and is a monitored hospital drug.

Is oxytocin banned in sport?

It is not named on the 2026 WADA Prohibited List and has no established performance-enhancing mechanism, so the best-supported conclusion is that it is permitted — but this is an inference, not a confirmed entry. Athletes should verify via GlobalDRO and check any compounded product for prohibited co-ingredients.

Primary sources

References

PubChem CID 439302PubChem CID 439302 (Oxytocin)
PMID 10949753Stubbs, Clin Obstet Gynecol 2000 (oxytocin for labor induction)
PMID 31032882Salati et al., Cochrane Database Syst Rev 2019 (prophylactic oxytocin, third stage)
PMID 15931222Kosfeld et al., Nature 2005 (oxytocin increases trust in humans)
PMID 17137561Domes et al., Biol Psychiatry 2007 (oxytocin improves 'mind-reading')
PMID 32514040Declerck et al., Nat Hum Behav 2020 (registered replication on oxytocin and trust — null)
PMID 26210057Walum et al., Biol Psychiatry 2016 (statistical/methodological critique of intranasal OT)
PMID 26581735Nave et al., Perspect Psychol Sci 2015 (does oxytocin increase trust? critical review)
PMID 26049207Leng & Ludwig, Biol Psychiatry 2016 (intranasal oxytocin: myths and delusions)
PMID 11274341Gimpl & Fahrenholz, Physiol Rev 2001 (the oxytocin receptor system)
DailyMed (Pitocin)Pitocin (oxytocin injection, USP) FDA Prescribing Information
WADA 2026WADA 2026 Prohibited List (oxytocin not named — permitted by inference)

Research use only · Not medical advice · Updated 2026-06-01